PD-1 mediates functional exhaustion of activated NK cells in patients with Kaposi sarcoma

Asma Beldi-Ferchiou1,2,3, Marion Lambert1,2, Stéphanie Dogniaux4

  • 1Institut National de Recherche Médicale (INSERM) UMR1149, Centre de Recherche Sur l'Inflammation, Équipe Immunité Innée Chez l'Enfant, Hôpital Robert Debré, Paris, France.

Oncotarget
|September 24, 2016
PubMed

Insights

Programmed Death-1 (PD-1) is upregulated on Natural Killer (NK) cells in Kaposi sarcoma patients, leading to impaired NK cell function and exhaustion. Targeting the PD-1 pathway may enhance anti-tumor immunity by overcoming this exhaustion.

Area of Science:

  • Immunology
  • Cancer Biology
  • Cellular Immunology

Background:

  • Programmed Death-1 (PD-1) is an inhibitory receptor on lymphocytes, crucial for immune regulation.
  • Cancer cells exploit PD-1 to evade immune responses by causing T-cell exhaustion.

Purpose of the Study:

  • To investigate the role of PD-1 in Natural Killer (NK) cell function in Kaposi sarcoma (KS).
  • To determine if PD-1 contributes to NK cell exhaustion in the context of cancer.

Main Methods:

  • Flow cytometry to detect PD-1 expression on NK cells from KS patients.
  • Ex vivo functional assays to assess NK cell responsiveness (degranulation, cytokine release).
  • In vitro experiments using PD-1-transduced NKL cells and prolonged NK cell stimulation.

Main Results:

  • PD-1 is upregulated on a subset of activated, mature NK cells in KS patients.
  • PD-1-expressing NK cells exhibit hyporesponsiveness to activation signals and reduced IFNγ production.
  • Exogenous IL-2 or IL-15 can restore the function of PD-1-positive NK cells.
  • In vitro induction of PD-1 on healthy NK cells mimics the impaired function observed in KS patients.

Conclusions:

  • PD-1 plays a critical role in mediating NK cell exhaustion in Kaposi sarcoma.
  • Upregulation of PD-1 on NK cells represents a mechanism of tumor immune evasion.
  • Targeting the PD-1 pathway could be a therapeutic strategy to enhance NK cell-mediated anti-tumor immunity.